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ABSTRACT 
Background and aims: Meta-analyses of randomised controlled trials (RCTs) have suggested a 
possible benefit of statin treatment on the risk of venous thromboembolism (VTE), with potential 
differences by type and dose of statins. We aimed to assess differences among statins and 
investigate the relationship between risk of VTE and reduction of LDL-cholesterol (LDL-c) levels. 
 
Methods: We electronically searched through November 29, 2017 RCTs comparing a statin with 
either placebo or another statin, including 100 or more adult participants and lasting at least 24 
weeks. Data on first VTE events and LDL-c were analysed with a network meta–analysis and a meta–
regression. 
 
Results: Thirty RCTs (159,058 participants; 1,431 events) were included, with 28 reporting LDL-c 
data. Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and 
other statins; 50% of the effect of statins on VTE risk reduction, however, was explained by their 
different potencies in lowering LDL-c. The risk reduction in VTE was proportional to LDL-c decrease 
(37% relative lower risk per each 1 mmol/L reduction in LDL-c), without an apparent threshold. A 
reduction of 1 mmol/L in LDL-c would translate in 37 less VTE events per year in 100,000 people in 
UK, corresponding to 3,162 prevented episodes per year in people between 50-59 years. 
 
Conclusions: In RCTs with statin treatment, the reduction of VTE risk was only partially related to 
LDL-c reduction and the benefit was larger than that observed for atherothrombotic risk. Further 
RCTs are warranted to clarify the relationship between statin, lipid modifications, and VTE risk. 
 
 
Key words: Venous thromboembolism; statin; meta-analysis; LDL-cholesterol; clinical trials  
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INTRODUCTION 
Statin treatment remains a cornerstone for the primary and secondary prevention of cardiovascular 
disease (CVD) [1]. Substantial evidence from individual participant data meta-analyses indicates a 
reduction of CVD risk proportional to the decrease in low-density-lipoprotein cholesterol (LDL-c) 
levels, either in randomised controlled trials (RCTs) of statin vs placebo or more intensive vs less 
intensive statin treatment [2, 3].  
Beyond LDL-c reduction, other “pleiotropic” mechanisms could contribute to the beneficial effects of 
statins on atherosclerosis, including platelet inhibition, reduction of inflammation, and modulation 
of endothelial function [4, 5]. As there is only a partial overlap between arterial and venous 
thrombosis risk factors [6], the pleiotropic effects of statins could also explain the reduced risk of 
venous thromboembolism (VTE) observed in some RCTs. Available systematic reviews and study-
level meta-analyses report divergent results on the efficacy of statin in the prevention of VTE and 
potential differences among different statins [7-9]. Moreover, the magnitude of the reduction of VTE 
risk related to LDL-c decrease remains to be established.   
Very few RCTs have reported direct “head-to-head” comparisons between statins. When direct 
evidence is limited, network meta–analysis is considered the methodology of choice to estimate the 
comparative effectiveness of multiple treatments [10]. The method is based on the joint analysis of 
direct evidence (RCTs with treatments of interest) and indirect evidence (RCTs comparing 
treatments of interest with a common comparator). In this view, the objective of this research was 
three-fold. First, we aimed to clarify previous inconsistencies on a possible statin class effect by 
comparing statins using a network meta-analysis. Second, in light of the evidence of an inverse linear 
relationship between LDL-c reduction and risk of arterial thrombosis, we investigated the shape and 
quantified the strength of the association between risk of VTE and LDL-c reduction. Third, from a 
public health perspective, we contextualised our result estimating the absolute benefit of different 
statin treatments using contemporary epidemiological data of VTE in the UK.  
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MATERIALS AND METHODS 
 
Search Strategy and Study Selection 
We performed this analysis of a previously registered systematic review protocol following standard 
guidelines for conducting and reporting network meta-analysis (checklist in the Supplemental 
Material) [7, 11-13]. We searched PubMed, ISI Web of Science, and the Cochrane Library for RCTs 
published in any language between March 1st, 2012 and November 29th, 2017 and comparing statin 
vs placebo/no treatment or statin vs statin; this time frame allowed update of the meta-analyses by 
Kunutsor et al. and Rahimi and et al. (Supplemental Material Figure S1) [7, 8]. Key-words used for 
searches combined terms related to treatment (including specific statins) and outcomes (search 
strategy reported in the Supplemental Material). Two authors independently performed the 
literature search and RCTs (open or blinded trials) were deemed eligible for inclusion if they enrolled 
at least 100 adult participants and lasted 24 weeks or more and reported VTE events. Reference lists 
of selected studies, as well as previous systematic reviews and meta-analyses, were manually 
scanned for additional relevant data and studies.  
 
Data Extraction and Quality Assessment  
After the identification of the eligible studies, two authors independently extracted data using 
standardised pre–defined forms. Data were extracted on: first author name, clinical trial registration 
number, trial acronym, PubMed identification number, year of journal article publication, statin 
treatment and comparator, duration of follow-up, sample size, gender distribution, mean (or 
median) age, arm-specific number of participants and participants with event in patients who were 
randomised and received treatment, and baseline and follow-up LDL-c levels. When studies reported 
LDL-c data for different durations of follow-up, the longest was used. Study quality was assessed 
using the Cochrane risk of bias tool [14].  
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Data Synthesis and Analysis 
We undertook a network meta–analysis within a frequentist model using the method of multivariate 
meta–analysis and assuming that all treatment contrasts have the same heterogeneity variance [15, 
16]; we assessed consistency between direct and indirect evidence by using the ‘design by 
treatment’ interaction model and expected that participants of the included RCTs could be randomly 
allocated to any of the treatments being compared [17]. We summarised the available evidence with 
a network diagram [18], reported characteristics and summary data of included RCTs in tables, and 
plotted the estimated odds ratios (ORs) vs a common comparator (placebo) in a forest plot. If one 
arm reported zero events, ORs were calculated using the “opposite-arm” continuity correction to 
account for the imbalance in the number of participants between the two arms [19]. Comparisons 
among statins were reported in tables, as previously advocated [20], and ranking probabilities for 
each statins were displayed in bar plots. Lastly, we evaluated the association between study size and 
result with a comparison-adjusted funnel plot [18]. 
We calculated rates of VTE events for each arm of the included RCTs dividing the number of VTE 
events (numerator) by the product of mean/median follow-up and number of participants (i.e., 
person-years; denominator). We further investigated the relationship between VTE risk and LDL-c 
reduction with a univariate meta-regression using the natural log of study-specific odds ratio as 
dependent variable and the between-arm percentage reduction of LDL-c as the independent 
variable [21, 22]. We first estimated within-arm percentage difference of LDL-c comparing end of 
follow-up vs baseline (i.e., 100
Final value−Baseline value
Baseline value
); then, the difference of the percentages 
between the two arms (statin vs placebo or more intensive vs less intensive statin) was used as 
independent variable. We opted to calculate percentage (i.e., relative) rather than absolute 
differences to account for potential imbalance of LDL-c levels at baseline. Given the possible non-
linearity of the association, we also modelled the independent variable using cubic splines with 4 
knots (at 5, 35, 65, and 95 percentile of its distribution)[23] and performed a weighted least-squares 
linear regression being the weight the inverse of study-specific variance; the two models (linear vs 
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non-linear) were then compared using the Akaike information criterion. Finally, we calculated the 
corresponding risk (CR) of VTE per 100,000 person-years (assuming a causal relationship between 
statin treatments and incident VTE) using the formula CR = 105
OR∗ACR
1−ACR+(OR∗ACR)
 [24]; ORs for 20% 
to 60% reduction of LDL-c were derived from the current meta-regression while the assumed control 
risk (ACR) for first unprovoked VTE was retrieved from the analysis of primary care patients in UK 
(Clinical Practice Research Datalink) [25]. CR and ACR data allowed the estimation of potentially 
avoidable number of VTE events associated with statin treatment and, along with data on mid-year 
population by age groups in UK in 2015 [26], to quantify avoidable events in UK. For the estimations 
of potential effects at a population level, we first confirmed with meta-regressions that the risk 
reduction of VTE was homogenous across different levels of age and sex; similarly, we also assessed 
whether the reduction of VTE risk differed according to the prevalence of CVD in RCTs participants 
(only primary prevention participants, only secondary prevention, both). 
Stata 14.1 (Stata Corp, College Station, TX, USA) was used for all analyses; we considered p<0.05 as 
statistically significant.   
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RESULTS 
Characteristics of Included Studies 
After duplicates exclusion and selection of articles by title and abstract, 380 recently published 
articles were found from the update search between March 1st, 2012 and November 29th, 2017 and 
none fulfilled the inclusion criteria. Of the 30 RCTs published before March 1st, 2012, information on 
LDL-c was not available in five RCTs; a manual search of references allowed extraction of LDL-c 
information from three other reports [27-29], leaving 28 out of 30 RCTs with available LDL-c data 
(Figure S1). 
The characteristics and the references of the included RCTs are reported in Table 1 and 
Supplemental Material Table S1 and S2: studies were published between 1998 and 2016, enrolled 
159,058 (range, 108 to 20,536) participants with 1,431 (range, 1 to 346) incident VTE episodes, had a 
median follow-up of 3.9 (range, 1 to 6.7) years with VTE rates ranging from 0 to 55.6 per 1000 
person-years (Table S2); baseline age weighted mean was 63.6 (range, 48 to 75) years and 70.1 
(range, 48 to 75) % were men (Figure S2). For the 28 RCTs with available information on cholesterol, 
the baseline LDL-c weighted mean was 3.33 mmol/L (range, 2.51 to 8.33). Twenty-three RCTs 
compared a statin vs placebo and seven compared two different statins. Six different statins were 
investigated (four doses of atorvastatin; three of rosuvastatin and simvastatin; two of pravastatin; 
and one of fluvastatin and lovastatin) reporting on overall 17 different pairwise comparisons.  
The risk of bias was deemed low, high, and unclear in 65.6%, 3.9%, and 30.5% of the cases, 
respectively (Table S3); high or unclear domain-specific bias was lowest for “selective reporting” 
(6.7%) and highest for “incomplete outcome data” (93.3%).  
 
Network Meta-Analysis and Meta-Regression 
The network of evidence is shown in Figure 1 while differences for each statin vs placebo and cross 
comparisons among statins in Figure S3 and in Table 2, respectively. When compared to placebo, the 
results of the network meta-analysis showed a lower risk of VTE for both rosuvastatin 10mg (OR 
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0.56; 95% confidence interval (CI): 0.37 to 0.83) and 20mg (0.57; 0.37 to 0.86); and for atorvastatin 
10mg (0.66; 0.47 to 0.94) (Figure S3). When compared against each other, rosuvastatin 10mg and 
20mg showed a greater reduction of the risk of VTE vs pravastatin 40mg, atorvastatin 80mg, and 
simvastatin 40mg (Table 2): ORs of VTE were 0.50 (0.31 to 0.80) and 0.50 (0.31 to 0.82) for 
rosuvastatin 10mg and 20mg, respectively, when compared to pravastatin 40mg; 0.55 (0.33 to 0.93) 
and 0.56 (0.33 to 0.96) when compared to atorvastatin 80mg; and 0.59 (0.38 to 0.93) and 0.60 (0.38 
to 0.96) when compared to simvastatin 40mg. The risk was also lower for rosuvastatin 40mg when 
compared to simvastatin 20mg (OR 0.49; 0.24 to 1.00); and for atorvastatin 10mg when compared to 
both atorvastatin 80mg (0.66; 0.46 to 0.93) and pravastatin 40mg (0.59; 0.39 to 0.89). The ranking 
probabilities showed a higher probability for rosuvastatin at a dose of 40mg to be the best 
treatment (39.6% to rank first), followed by the lower doses of 10mg (18.2%) and 20mg (16.2%) 
(Figure S4 and Figure S5). There was no evidence of inconsistency in the network of comparisons 
(p=0.538) and the visual inspection of the comparison-adjusted funnel plot did not suggest 
publication bias (Figure S6). 
The meta-regression analyses showed no different reductions in VTE risk with statin treatments 
comparing men and women (p=0.740) or across mean ages of included participants (p=0.428) 
(Figure S7). Conversely, there was an inverse linear relationship between the risk of VTE and the LDL-
c reduction (Figure 2). Change in LDL-c levels explained 51.2% in the VTE risk reduction, with an 
estimated 14.4% (95% confidence interval (CI): 0.2, 26.6; p=0.047) lower risk of VTE per each 10% 
reduction of LDL-c, corresponding to 37.3% (95% CI: 0.6, 60.4) per 1 mmol/L (i.e., 30% reduction of 
LDL-c in this meta-analysis). These estimates indicate an absolute benefit in the UK population 
ranging from 14 less cases of first VTE events per 100,000 person per year in subjects between 30 to 
39 years with a 20% reduction of LDL-c to 199 less cases in subjects between 70-79 years with 60% 
LDL-c reduction; these figures translate in 1217 and 9707 fewer VTE cases per year, respectively 
(Figure 3). 
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AIC values did not suggest a non-linear relationship between LDL-c change and risk of VTE (21.9 for 
the linear vs 24.6 for the non-linear model, with lower values indicating better model) and, 
accounting for LDL-c reduction, there was no difference in the reduction of VTE risk across RCTs 
including only participants in primary CVD prevention, only secondary prevention, or both (p=0.109; 
Table S1).    
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DISCUSSION 
In this analysis, we found differences among statins in the prevention of VTE, with a greater efficacy 
for rosuvastatin at any dose (10mg, 20mg, and 40mg) compared to other statins. Such differences, 
however, were mainly explained by dissimilarity among statins in their potency/intensity to reduce 
LDL-c. We estimated that 30% reduction in LDL-c, which equates to 1 mmol/L in our meta-analysis, 
would reduce the risk of VTE on mean by 37%. This beneficial effect seemed to be continuous, 
without any apparent threshold. 
 
Added value to previous meta-analysis on the same topic 
Systematic investigations of both observational and RCTs have not clarified whether the risk 
reduction of VTE with statins is a class effect [7, 8, 30]. While differences among statins for the 
secondary prevention of venous thromboembolism in observational studies have not been 
investigated [30, 31] or demonstrated [32], on the basis of 22 RCTs comparing statins vs placebo 
Rahimi et al. concluded that there was no good evidence of a variation by specific statin treatment 
[8]. More recently, Kunutsor et al. suggested a larger benefit for rosuvastatin compared to other 
statins combining data from 23 statin vs placebo in RCTs [7]. Both analyses, however, did not include 
“head-to-head” RCTs, given the difficulties of pooling together studies investigating statin vs placebo 
and statin vs statin with a standard pairwise meta-analysis, which can compare only two 
interventions at a time. In the last years, the introduction of NMA is allowing researchers to combine 
information from RCTs reporting different pairwise comparisons and rank competing interventions 
combining direct and indirect evidence. NMA approach has been adopted within the technology 
appraisal from multiple countries and is considered the “gold standard” to compare the complete 
set of treatments [33]. The result of this NMA evidenced some differences among statins, indicating 
that rosuvastatin at any dose has the larger probability to reduce the risk of VTE compared to other 
statins. From this perspective, our findings corroborate and reinforce the differences observed in the 
previous meta-analysis while adding also evidence from “head-to-head” RCTs [7].  
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In the last decades, the importance of cholesterol in determining cardiovascular risk and the pivotal 
role of lowering cholesterol with statins to reduce cardiovascular events has been clearly 
demonstrated. In observational studies, populations with low LDL-c levels experience a lower risk of 
cardiovascular events and most cardiovascular risk prediction models require information on 
cholesterol levels [34]. At the same time, results from multiple, large international RCTs have 
undoubtedly demonstrated that lowering LDL-c with statins reduces the risk of cardiovascular 
disease [1]. In particular, insights into the relationship between LDL-c, statins, and cardiovascular 
atherosclerotic events has emerged from individual participant data meta-analyses of RCTs, 
indicating a strong, linear inverse association between LDL-c reduction and risk of atherothrombosis. 
The Cholesterol Treatment Trialists’ Collaborators (CTT) meta-analysis reported a 21% relative risk 
reduction of major vascular atherothrombotic events per 1 mmol/L reduction of LDL-c combining 
statin vs placebo RCTs [2]; a similar estimate was found combining RCTs with more intensive vs less 
intensive statin treatment (26% risk reduction per 1mmol/L lower LDL-c) [3]. In a recent review, 
however, Gaertner et al. underlined that the putative preventive effects of statins on VTE appear to 
be independent of the LDL-c reduction highlighting, at the same time, that a dose-response 
relationship has not been demonstrated [35]. Our study indicates a relative risk reduction of 37% per 
1 mmol/L of LDL-c, which is higher than estimates for atherothrombotic events. Such higher benefit 
on venous compared to arterial thrombosis, along with the findings that around 50% of the statin 
effects on the risk VTE is explained by LDL-c reduction, would underline that pleiotropic mechanisms 
play an important role in the prevention of VTE beyond LDL-c reduction.  
 
Potential mechanisms related to VTE risk reduction with statins 
Pre-clinical and clinical studies in the last two decades have investigated the effects of statins on 
multiple mechanisms of venous thrombosis. The three main pathophysiological determinants of VTE 
are classically considered to be blood stasis, hypercoagulability, and endothelial dysfunction, and 
two of these factors are directly modulated by statin therapy. In fact, statins have been shown to 
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influence the coagulation process via different pathways, including a reduced thrombin 
formation,[36] inhibition of plasminogen activator inhibitor 1 synthesis [37], enhanced fibrinolysis 
[38], and reducing platelet activity [39]. In this circumstance, the “anti-platelet” activity of statin 
could be particularly relevant because individual-participant data from the two largest placebo-
controlled RCTs investigating aspirin and VTE have shown a 32% relative reduction of a recurrent 
VTE after a first unprovoked event in patients randomised to aspirin [40]. Statins have also effects on 
the endothelial function, increasing the expression of thrombomodulin, the synthesis of nitric oxide 
and prostacyclin, and reducing oxidative stress via a downregulation of NADPH oxidase expression 
[39]. These anti-coagulative, anti-platelet, and endothelial mechanisms, along with anti-
inflammatory properties, could explain the larger effect of statins for venous as compared to arterial 
thrombosis. Lastly, it should be also noted that an observational retrospective analysis did not find a 
reduced risk of VTE events in patients treated with lipid-lowering agents other than statins [41-43], 
further suggesting that pleiotropic mechanisms could contribute to the beneficial effects of statins 
on the risk of venous thrombosis. 
   
Strengths and limitations 
Our studies has several strengths. Compared to previous meta-analyses, we used a NMA approach 
combining all available evidence in a single analysis to compare multiple treatments and estimate, 
for each of them, the probability to be the best for the reduction of VTE risk. We also performed a 
meta-regression to investigate the shape of the association (linear vs non-linear) and clarify whether 
potential differences observed in the NMA could be explained by dissimilar potencies of statins; for 
this analysis, we included 28 studies compared to the 23 reported in a previous analysis [8], thus 
enhancing the statistical power. Lastly, we quantified the public health implications of our results 
using updated data on the incidence of VTE in UK. Some limitations should also be considered while 
interpreting these findings. First, available data did not allow stratification of VTE events into 
provoked or unprovoked and very sparse information specifically on pulmonary embolism and deep 
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vein thrombosis were reported. Second, information on LDL-c was not available for all studies and, in 
some circumstances, was reported either for a different follow-up compared to the end of the study 
or for a subsample of the included participants. However, when multiple follow-up data were 
available, we selected the longest. Third, in the estimations of the potential effects of statin at 
population level, we assumed the risk reduction to be homogenous across different levels of age and 
sex, in line with the results of our meta-regressions (no effects of age and sex) and with those of the 
CTT collaboration for atherothrombotic events [2, 3, 44]. Moreover, we considered UK because we 
found published data on the epidemiology of VTE for this country, although our estimates could be 
similarly applied to other countries with available data on VTE epidemiology. Fourth, limitations of 
the analytical procedures should also be acknowledged. Heterogeneity of studies is a common 
drawback for both NMAs and meta-regressions [22, 45]. Some characteristics (participants enrolled, 
duration of follow-up, background therapies, and quality of studies) differed among included RCTs: 
this could justify both differences in the incidence rates (i.e., absolute risk) of VTE across RCTs and 
the wide confidence intervals observed in some NMA comparisons and in the meta-regression 
estimate. However, we did not find inconsistency in the network of comparisons. Furthermore, 
although the original studies were randomised and there is a substantial clinical and pre-clinical 
evidence on the lowering effects of statins on LDL-c, the relationship between LDL-c reduction and 
VTE in the meta-regression is across trials and therefore observational [22]. Nonetheless, LDL-c could 
at least be considered a marker of the beneficial effects of statins on VTE risk reduction. Fifth, the 
direction of the association between a biomarker and an outcome could be different when explored 
at individual level (i.e., within a RCT) or across multiple RCTs (“ecological bias”) [22]. Lastly, the 
results of the NMA indicated a larger reduction of VTE risk comparing atorvastatin 10mg vs 
atorvastatin 80mg, in apparent contrast with the meta-regression finding. There are two possible 
reasons. First, it is not uncommon in meta-analyses to obtain an overall estimate which is in contrast 
with one (or more) single study estimate, particularly in the presence of heterogeneity across 
studies. Moreover, only around 50% of the statin effect is explained by LDL-c reduction. Second, it 
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was not possible to account for change in LDL-c reduction in the NMA because of the sparsity of the 
network (there were only single comparisons for fluvastatin, lovastatin, and rosuvastatin 20mg). 
 
Conclusions 
Our results would indicate that differences among statins and their doses in the prevention of VTE 
are related to their different potency in reducing LDL-c, suggesting that the relationship between 
LDL-c decrease and the risk of vascular events could hold not only for arterial but also venous 
thrombosis. The risk reduction for the same decrease of LDL-c, however, was larger for VTE 
compared to major atherosclerotic events, which would postulate that mechanisms other than LDL-c 
reduction could be involved in the prevention of VTE with statin treatment.  
Venous thromboembolism remains a significant clinical and public health problem. Recent data 
indicate an overall incidence, in the general population, of 107 first non-cancer-related VTE episodes 
per 100,000 people per year and a 7% mortality one year after the event [25, 46]. Once VTEs occur, 
anticoagulants represent the cornerstone for treatment; there are, however, no strategies for the 
primary prevention of unprovoked VTE in the general population and the optimal risk/benefit 
preventive approach still needs to be defined. Given the increasing prevalence of multimorbid 
elderly patients at an increased risk of VTE [25], statin treatment could be an effective low-cost 
option to reduce the risk of first VTE events: at a cost of one more case of myopathy, 10-20 more 
cases of diabetes, and 1-2 more cases of haemorrhagic stroke per 10,000 people per year with a 50% 
reduction of LDL-c [1], the same reduction would also result in 5-10 less cases of VTE in people 
between 50-70 years. 
These results of this analysis should further encourage to design appropriate RCTs (with VTE as 
primary outcome) and to perform collaborative individual-participant data meta-analysis aiming: to 
shed light on the efficacy and safety of statins in the prevention of venous events; to clarify the 
nature, shape, and strength of the association with LDL-c reduction in better detail; to investigate 
the heterogeneity of effects according to relevant clinical characteristics and identify patients whose 
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benefit/risk is optimal (stratified medicine); and to estimate the absolute benefit and risk. Answers 
to these questions are relevant, given the likely increase of VTE incidence in the future, the absence 
of a defined strategy to prevent the risk of first unprovoked VTE events, and the excellent 
benefit/risk profile and the low cost of available statins. 
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Figure 1: Network map 
Legend: Nodes represent the competing treatments and edges the available direct comparisons between 
pairs of treatments. Nodes and edges are weighted according to the number of studies involved in each 
treatment and comparison, respectively 
* Doses were 20mg and 40mg for each half of participants in the randomised controlled trial 
 
Figure 2: Association between risk of venous thromboembolism and LDL-c reduction 
Legend: The plotted data show the relationship between risk of venous thromboembolism and LDL-c reduction. 
The dotted line indicates the predicted correlation and the grey area the 95% confidence interval (CI). Each 
circle represents a randomised controlled trial and its size is proportional to the inverse of study variance. The 
risk of venous thromboembolism was reduced by 37.3% (95% CI: 0.6, 60.4) per each 30% (i.e., 1 mmol/L) 
reduction of LDL-c; Adjusted R2=51.2% 
 
Figure 3: Number of avoided venous thromboembolism events associated with LDL-c reduction 
with statins 
Legend: Age groups and LDL-c reductions were selected to be consistent with values reported in included 
randomised controlled trials. Age-specific data for venous thromboembolism incidence and mid-year 
populations were obtained from CPRD [25] and ONS [26], respectively. 
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Table 1: Characteristics of the included studies 
 
    Arm 1  Arm 2       
Study 
 Publication 
Year 
 
Intervention Participants Events 
 
Intervention Participants Events 
 Follow-up 
(years) 
Males 
(%) 
Diabetes 
(%) 
Aged 
(years) 
Available 
LDL-c data 
ASCOT-LLA  2003  Atorvastatin 10mg 5168 13  Placebo 5137 20  3.2 65 25 81 ✓ 
CARDS  2004  Atorvastatin 10mg 1428 14  Placebo 1410 26  3.9 62 100 68 ✓ 
ASPEN  2006  Atorvastatin 10mg 948 4  Placebo 916 10  4.3 61 100 66 ✓ 
LORD  2010  Atorvastatin 10mg 64 1  Placebo 68 1  2.5 62 8 65 ✓ 
4D  2005  Atorvastatin 20mg 619 13  Placebo 636 13  3.9 66 100 54 ✓ 
Sola et al.  2006  Atorvastatin 20mg 54 3  Placebo 54 2  1.0 54 0 33 ✓ 
ALLIANCE  2004  Atorvastatin 40mga 1217 9  Placebo 1225 10  4.3 61 22 82 ✓ 
SALTIRE  2005  Atorvastatin 80mg 77 0  Placebo 78 1  2.2 68 5 70 ✓ 
SPARCL  2006  Atorvastatin 80mg 2365 34  Placebo 2366 29  4.9 63 17 60 ✓ 
LEADe  2010  Atorvastatin 80mg 314 2  Placebo 326 1  1.5 74 - 48 ✓ 
TNT  2005  Atorvastatin 80mg 4995 47  Atorvastatin 10mg 5006 37  4.9 61 15 81 ✓ 
PROVE IT–TIMI 22  2004  Atorvastatin 80mg 2099 17  Pravastatin 40mg 2063 16  2.0 58 18 78 ✓ 
REVERSAL  2004  Atorvastatin 80mg 328 0  Pravastatin 40mg 329 1  1.5 56 19 72 ✓ 
IDEAL  2005  Atorvastatin 80mg 4439 33  Simvastatin 20mg 4449 37  4.8 62 12 81 ✓ 
ASAP  2001  Atorvastatin 80mg 160 1  Simvastatin 40mg 165 0  2.0 48 - 39 ✓ 
                 
ALERT  2003-4  Fluvastatin 40mg 1050 23  Placebo 1052 23  5.1 50 19 66 ✓ 
                 
AFCAPS/TexCAPS  1998  Lovastatin 20mgb 3304 9  Placebo 3301 12  5.3 58 4 85 ✓ 
                 
MEGA  2006  Pravastatin 10mgc 3866 3  Placebo 3966 1  5.3 58 21 30 ✓ 
LIPID  1998  Pravastatin 40mg 4512 79  Placebo 4502 74  5.6 62 9 83 ✓ 
PREVEND IT  2004  Pravastatin 40mg 433 3  Placebo 431 2  3.8 51 3 65 ✓ 
PROSPER  2002-11  Pravastatin 40mg 2834 28  Placebo 2865 20  3.2 75 11 47 ✓ 
                 
CORONA  2007  Rosuvastatin 10mg 2514 15  Placebo 2497 28  2.7 73 30 76 ✓ 
GISSI-HF  2008  Rosuvastatin 10mg 2285 9  Placebo 2289 9  3.9 68 26 77 ✓ 
HOPE-3  2016  Rosuvastatin 10mg 6361 14  Placebo 6344 31  5.6 66 6 54 ✓ 
JUPITER  2008-9  Rosuvastatin 20mg 8901 34  Placebo 8901 60  1.9 66 0 62 ✓ 
METEOR  2007  Rosuvastatin 40mg 700 1  Placebo 281 0  2.0 60 0 57 ✓ 
ASTRONOMER  2010  Rosuvastatin 40mg 134 0  Placebo 135 1  3.5 58 0 61 ✓ 
                 
HPS  2002  Simvastatin 40mg 10269 168  Placebo 10267 178  5.0 64 36 75  
A-Z  2004  Simvastatin 80mg 2265 10  Simvastatin 20mg 2232 8  2.0 61 24 76 ✓ 
SEARCH  2010  Simvastatin 80mg 6031 90  Simvastatin 20mg 6033 103  6.7 64 37 83  
 
References are reported in Table S1 in the supplementary material 
 
LDL-c = Low-density lipoprotein cholesterol 
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a Median dose 
b Doses were 20mg and 40mg for each half of participants in the RCT 
c Mean dose 
d Mean or median 
Table 2: Cross-comparisons of individual statins for risk of venous thromboembolism 
             Simvastatin 
80mg 
            Simvastatin 
40mg 
1.09 
(0.55,2.13) 
           Simvastatin 
20mg 
0.83 
(0.45,1.53) 
0.90 
(0.68,1.18) 
          Rosuvastatin 
40mg 
1.68 
(0.11,25.09) 
1.39 
(0.10,19.68) 
1.51 
(0.10,22.85) 
         Rosuvastatin 
20mg 
1.20 
(0.08,17.40) 
2.01 
(0.98,4.10) 
1.66 
(1.04,2.66) 
1.80 
(0.84,3.88) 
        Rosuvastatin  
10mg 
1.01 
(0.56,1.81) 
1.21 
(0.08,17.54) 
2.03 
(1.00,4.10) 
1.68 
(1.07,2.65) 
1.82 
(0.86,3.88) 
       Pravastatin  
40mg 
0.50 
(0.31,0.80) 
0.50 
(0.31,0.82) 
0.60 
(0.04,8.53) 
1.00 
(0.55,1.84) 
0.83 
(0.59,1.16) 
0.90 
(0.46,1.76) 
      Pravastatin  
10mg 
0.37 
(0.04,3.58) 
0.18 
(0.02,1.81) 
0.18 
(0.02,1.83) 
0.22 
(0.01,7.13) 
0.37 
(0.04,3.81) 
0.30 
(0.03,2.96) 
0.33 
(0.03,3.47) 
     Lovastatin 
20mga 
4.11 
(0.36,46.42) 
1.51 
(0.61,3.72) 
0.75 
(0.29,1.94) 
0.75 
(0.29,1.98) 
0.90 
(0.06,14.58) 
1.51 
(0.53,4.29) 
1.25 
(0.51,3.06) 
1.36 
(0.46,3.99) 
    Fluvastatin  
40mg 
0.75 
(0.26,2.12) 
3.07 
(0.30,31.83) 
1.13 
(0.59,2.13) 
0.56 
(0.27,1.13) 
0.56 
(0.27,1.16) 
0.67 
(0.05,10.11) 
1.13 
(0.50,2.57) 
0.94 
(0.50,1.74) 
1.02 
(0.43,2.42) 
   Atorvastatin  
80mg 
0.99 
(0.50,1.94) 
0.74 
(0.29,1.87) 
3.04 
(0.31,29.98) 
1.11 
(0.76,1.64) 
0.55 
(0.33,0.93) 
0.56 
(0.33,0.96) 
0.67 
(0.05,9.59) 
1.12 
(0.70,1.79) 
0.93 
(0.62,1.38) 
1.01 
(0.58,1.73) 
  Atorvastatin  
40mg 
1.12 
(0.43,2.93) 
1.11 
(0.38,3.25) 
0.83 
(0.24,2.89) 
3.40 
(0.30,38.93) 
1.25 
(0.49,3.19) 
0.62 
(0.23,1.66) 
0.62 
(0.23,1.69) 
0.75 
(0.05,12.21) 
1.25 
(0.43,3.66) 
1.04 
(0.41,2.62) 
1.12 
(0.37,3.40) 
 Atorvastatin  
20mg 
0.83 
(0.26,2.62) 
0.93 
(0.42,2.04) 
0.92 
(0.36,2.31) 
0.69 
(0.22,2.11) 
2.82 
(0.26,30.27) 
1.03 
(0.48,2.21) 
0.51 
(0.23,1.16) 
0.52 
(0.23,1.19) 
0.62 
(0.04,9.57) 
1.04 
(0.41,2.60) 
0.86 
(0.41,1.81) 
0.93 
(0.36,2.43) 
Atorvastatin 
10mg 
1.64 
(0.74,3.64) 
1.36 
(0.52,3.59) 
1.52 
(1.07,2.16) 
1.51 
(0.76,2.98) 
1.13 
(0.44,2.87) 
4.63 
(0.47,45.78) 
1.70 
(1.12,2.58) 
0.84 
(0.49,1.43) 
0.85 
(0.49,1.47) 
1.02 
(0.07,14.64) 
1.71 
(0.95,3.07) 
1.41 
(0.94,2.13) 
1.53 
(0.80,2.93) 
 
Comparisons are shown column vs row, i.e. Rosuvastatin 10mg is associated with an Odds Ratio for VTE of 0.55 compared to Atorvastatin 80mg [or, equivalently, Atorvastatin 80mg is 
associated with an Odds Ratio of 1.82 (=1/0.55) compared to Rosuvastatin 10mg]. Statistically significant differences are in bold. 
 
a Doses were 20mg and 40mg for each half of participants in the RCT 
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